Moderna (MRNA) Retained Earnings (2017 - 2026)
Moderna (MRNA) posted quarterly Retained Earnings of $5.1 billion for Q2 2026, down 38.2% year-over-year from $8.2 billion in Q2 2025, and down 13.3% on a QoQ basis from $5.9 billion in Q1 2026.
Moderna (MRNA) Retained Earnings (2017 - 2026) Analysis & Trends
Moderna has reported Retained Earnings for 10 years, with the latest figure at $5.1 billion in Q2 2026.
- Retained Earnings for Q2 2026 came in at $5.1 billion, down 38.2% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.1 billion (down 38.2% YoY), and the FY2025 annual result was $7.2 billion, down 28.09% from the prior year.
- Retained Earnings retreated to $5.1 billion in Q2 2026, from $5.9 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $18.4 billion in Q1 2023 and troughed at $5.1 billion in Q2 2026.
- A 5-year average of $12.0 billion and a median of $11.8 billion in 2024 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2022, when Retained Earnings soared 231.14%; it then sank 38.2% in 2026.
- A 5-year view of Retained Earnings shows it stood at $18.3 billion in 2022, then retreated by 25.73% to $13.6 billion in 2023, then declined by 26.17% to $10.0 billion in 2024, then fell by 28.09% to $7.2 billion in 2025, then retreated by 29.42% to $5.1 billion in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $5.1 billion in Q2 2026, $5.9 billion in Q1 2026, and $7.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.10 Bn |
| Mar 31, 2026 | 5.88 Bn |
| Dec 31, 2025 | 7.22 Bn |
| Sep 30, 2025 | 8.05 Bn |
| Jun 30, 2025 | 8.25 Bn |
| Mar 31, 2025 | 982.00 Mn |
| Dec 31, 2024 | 866.00 Mn |
| Sep 30, 2024 | 11.17 Bn |
| Jun 30, 2024 | 631.00 Mn |
| Mar 31, 2024 | -101.00 Mn |
| Dec 31, 2023 | -123.00 Mn |
| Sep 30, 2023 | 277.00 Mn |
| Jun 30, 2023 | 193.00 Mn |
| Mar 31, 2023 | 731.00 Mn |
| Dec 31, 2022 | 18.32 Bn |
| Sep 30, 2022 | 16.86 Bn |
| Jun 30, 2022 | -240.00 Mn |
| Mar 31, 2022 | -184.00 Mn |
| Dec 31, 2021 | 9.96 Bn |
| Sep 30, 2021 | 5.09 Bn |